Loading
The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.
Approved 2014 (relapsed CLL, RESONATE), 2016 (frontline, RESONATE-2), and with venetoclax as fixed-duration therapy (GLOW, CAPTIVATE; EU 2022). Also mantle cell lymphoma (withdrawn in the US 2023), Waldenström, marginal zone (withdrawn), and chronic GVHD. Off-target inhibition of EGFR, TEC, and CSK causes atrial fibrillation (~10-16%), hypertension, bleeding, and arthralgia; head-to-head trials (ELEVATE-RR, ALPINE) showed acalabrutinib and zanubrutinib are better tolerated, and zanubrutinib more effective, so ibrutinib is now second choice where alternatives exist.
Covalent binding to cysteine 481 in the BTK active site irreversibly blocks BCR signalling; also inhibits ITK, TEC, EGFR (off-target). Connects to BTK (Bruton tyrosine kinase).
1.B-cell receptor engagement activates BTK in the CLL cell
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Imbruvica was in the first group of ten drugs negotiated under the Inflation Reduction Act: the Medicare maximum fair price of $9,319 per 30-day supply took effect 1 January 2026, a 38% cut from the 2023 list price.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Several PBMs now prefer acalabrutinib or zanubrutinib over ibrutinib for CLL on the basis of head-to-head trials.
CMS fact sheet, Medicare Drug Price Negotiation Program negotiated prices for 2026 (2023). Net prices after rebates are usually lower.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap) · CMS: Medicare Drug Price Negotiation Program · CMS fact sheet: negotiated prices for 2026 (August 2024). Not medical or financial advice; verify with your plan.
Sources: NICE TA429 · SMC advice: ibrutinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2015-03-04 | Pharmacyclics to AbbVie (incl. ImmunoGen, Capstan) Ibrutinib (Imbruvica), shared with Johnson & Johnson | Acquisition | not disclosed | $21bn | source |
Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Mantle cell lymphoma (accelerated); first BTK inhibitor
Chronic lymphocytic leukemia after at least one prior therapy
Relapsed CLL
Chronic lymphocytic leukemia after at least one prior therapy
Confirmed: the accelerated approval of 2014 converted to traditional approval 0.5 years after it was granted.
First-line CLL
Adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
MCL and MZL indications voluntarily withdrawn after confirmatory trials missed
Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Withdrawn: the indication came off the label 9.5 years after its accelerated approval.
Adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
Withdrawn: the indication came off the label 6.3 years after its accelerated approval.
| Region | Year | Indication |
|---|---|---|
| US | 2013 | Relapsed mantle cell lymphoma (accelerated); first BTK inhibitor |
| US | 2014 | Relapsed CLL (RESONATE); del(17p) CLL |
| US | 2016 | First-line CLL (RESONATE-2) |
| EU | 2014 | Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation |
| EU | 2022 | Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE) |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Atrial fibrillation Pooled long-term CLL data; 5% grade ≥3 | 16% | - |
| Hypertension Cumulative over years | 42% | - |
| Major haemorrhage | 4% | - |
| Diarrhoea | 50% | - |
| Arthralgia | 30% | - |
Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (btk inhibitors) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Watch and wait remains the standard of care for early-stage chronic lymphocytic leukaemia irrespective of risk factors, even with a targeted drug available.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
Ibrutinib during induction and as maintenance should be part of first-line treatment for younger patients with mantle cell lymphoma; whether transplant adds anything to an ibrutinib-containing regimen is still being followed.
Twenty-eight extra months of progression-free survival, with no survival gain and a high rate of severe adverse events in both arms. It set up the two trials that followed: ECHO, which substituted a more selective inhibitor, and ENRICH, which removed the chemotherapy.
ELEVATE-TN put a more selective BTK inhibitor into first-line CLL and, with the head-to-head ELEVATE-RR trial, showed it is as effective as ibrutinib with fewer cardiac side effects. Continuous acalabrutinib became one of the two main front-line options alongside fixed-duration venetoclax combinations. The trade-off is indefinite therapy and cost versus a time-limited course.
ZUMA-2 gave patients with BTK-inhibitor-refractory mantle cell lymphoma, who previously had a median survival under a year, a therapy with durable remissions in a substantial fraction. Brexu-cel is now standard after BTK inhibitor failure and CAR-T is being tested earlier in the disease. Neurotoxicity rates are higher than in other lymphoma CAR-T trials.
A failure worth reading: the drug worked where patients could tolerate the regimen it was added to, and harmed where they could not. It is the strongest argument in lymphoma for designing first-line combinations around what an older patient can finish.
Query for this drug: (TITLE:"Ibrutinib" OR ABSTRACT:"Ibrutinib" OR TITLE:"Imbruvica" OR ABSTRACT:"Imbruvica") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ibrutinib, not a curated reading list.
Shares TEC, ITK, Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL), Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL).
Shares Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL), ASPEN (Waldenström macroglobulinaemia), Caution: ibrutinib in patients with cardiac risk, ALPINE.
Shares A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL), MIPI (Mantle Cell Lymphoma International Prognostic Index), ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors.
Shares A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4, CD79B ITAM mutation, MYD88 L265P and CXCR4 mutations, B-cell receptor / BTK signalling (to NF-κB).
Shares A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia, SYMPATICO, Fixed-duration vs continuous therapy, Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant).
Shares ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL, CLL13 / GAIA, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE.
Shares Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant), Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, MYD88 L265P and CXCR4 mutations.
Shares GLOW, CAPTIVATE, BTK inhibitor + venetoclax, fixed duration, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute.